Celltrion Pharmaceutical (CEO Jeong-Soo Seo) announced on the 25th that it recorded KRW 233.6 billion in sales, KRW 23.6 billion in operating profit, and KRW 29.3 billion in net income in 2020.
Compared to the same period of the previous year, sales increased 34.6%, operating profit and net profit increased by 60.3% and 143.4%, respectively, and sales, operating profit, and net profit all recorded the highest levels since the incorporation of Celltrion Group.
Celltrion Pharm said that the growth of all business divisions, including chemicals and biopharmaceuticals, was the driving force behind strong earnings. In particular, it is said that global chemical products, which have expanded in earnest from the third quarter of last year, are effective.
Celltrion Pharmaceutical’s flagship product, Godex, a soy sauce solution, recorded sales of about 65.7 billion won, the largest single item, and Remsima, Hezuma, and Truxima three antibody biosimilars recorded about 43.3 billion won, compared to the same period last year. It said that it achieved about 14% growth.
In addition, it was announced that six kinds of global chemical drugs, including the HIV (human immunodeficiency virus) treatment CT-G7, achieved sales of about 43 billion won by increasing production and shipments.
Accordingly, Celltrion Pharmaceutical plans to maximize the production efficiency of major items and focus on expanding earnings by reinforcing marketing, while preparing and managing new growth engines thoroughly.
In particular, ETC (prescription drugs), including items newly incorporated into the product lineup, such as’Dalbi Lee’,’Nesina’,’Actos’,’Wai2ben’, and’Albochill’, which secured sales rights at the end of last year. It plans to strengthen its targeting in the OTC (over-the-counter drug) market.
An official from Celltrion Pharmaceutical said, “Last year, we were able to accelerate our growth by improving production efficiency and expanding commercial production items, making achievements in the areas we prepared for a long time. This year, as we have secured a number of promising products such as’Remsima SC’ as well as new diabetes treatments and hypertension treatments, we expect to continue high growth based on product competitiveness.”
He added, “We will do our best to continue to grow steadily in various areas other than the liver disease treatment area, which has traditionally been strong.”
Copyright © Pax Economic TV Unauthorized reproduction and redistribution prohibited